<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION



                             Washington, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


                Date of Report (date of earliest event reported):
                                   May 1, 2001



                            HARVARD BIOSCIENCE, INC.
             (Exact Name of Registrant as specified in its charter)



         Delaware                    0-31923                    04-3306140
(State or other jurisdiction     (Commission File            (I.R.S. Employer
     of incorporation)               Number)                Identification No.)



                 84 October Hill Road, Holliston, MA 01746-1371
              (Address of principal executive offices and zip code)

                                 (508) 893-8066
              (Registrant's telephone number, including area code)



<PAGE>


ITEM 5.  OTHER EVENTS

                  As previously announced, on May 1, 2001 Harvard Bioscience,
Inc. (the "Company") acquired (the "Acquisition") the business of Warner
Instrument Corporation ("Warner"). In the Acquisition, the Company purchased
operating assets of Warner for a purchase price of $2.6 million in cash and the
assumption of certain operating liabilities. The Acquisition will be accounted
for using the purchase method. For the twelve-month period ended December 31,
2000, Warner had unaudited revenues of $2.3 million net of sales to the Company.

                  This Current Report on Form 8-K may contain forward-looking
statements within the meaning of the federal securities laws. Reliance should
not be placed on forward-looking statements because they involve known and
unknown risks and uncertainties which may cause the actual results, performance,
and achievements of the Company to differ materially from the anticipated future
results, performance and achievements that are expressed or implied by such
forward-looking statements. Additional information concerning these risks and
uncertainties is contained in the section entitled "Important Factors That May
Affect Future Operating Results" of the Company's Annual Report on Form 10-K for
the year ended December 31, 2000. The Company disclaims any obligation to update
any of the forward-looking statements contained herein to reflect future
developments or events.



<PAGE>


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated:   May 1, 2001                       HARVARD BIOSCIENCE, INC.



                                           By: /s/ DAVID GREEN
                                               ----------------------------
                                               David Green
                                               President



<PAGE>


                                  EXHIBIT INDEX


EXHIBIT NO.      DESCRIPTION

99.1             Press Release, dated May 1, 2001







<PAGE>

                                                                  Exhibit 99.1


            HARVARD BIOSCIENCE, INC. (TICKER: HBIO, EXCHANGE: NASDAQ)
                           NEWS RELEASE - MAY 1, 2001

              HARVARD BIOSCIENCE, INC. ACQUIRES WARNER INSTRUMENTS

HOLLISTON, Mass., May 1 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO)
today announced the acquisition of Warner Instruments Corporation, a leader in
innovative cell and tissue electro-physiology research products.

Formed in 1988, Warner Instruments designs, manufactures, and markets a wide
array of products for cell and tissue electro-physiology research. Located in
Hamden Connecticut, Warner Instruments employs 26 people. Burt Warner and Vic
Pantani, the company's co-founders, will continue on as President and Director
of Engineering to manage the day-to day operations of the business. The
acquisition of this complimentary range of innovative, high quality products
further strengthens Harvard Bioscience's already comprehensive offering of
research tools.

"Through internal development of new products, strategic alliances, licensing of
new technology and acquisitions, our goal is to expand the range of products we
offer for use in drug discovery, thereby growing revenues 30% to 35% per year,"
said Chane Graziano, CEO of Harvard Bioscience. "Since
 we acquired Harvard
Bioscience in March of 1996 and implemented this strategy, our compound annual
growth rate has been 32%. The acquisition of Warner is consistent with this
strategy and we believe it will be immediately accretive."

Harvard Bioscience is a global developer, manufacturer and marketer of
innovative, enabling tools in drug discovery research at pharmaceutical and
biotechnology companies, universities and government laboratories. HBIO sells
approximately 10,000 products to thousands of researchers in over 60 countries
though its 1,000 page catalog, and through its distributors, the most notable of
which is AP Biotech. HBIO has sales and manufacturing operations in the United
States, the United Kingdom, and Germany with sales facilities in France and
Canada, and distributors around the world.

This press release contains certain statements that are "forward-looking
statements" as that term is defined under the Private Securities Litigation
Reform Act of 1995 and releases issued by the Securities and Exchange
Commission, including statements regarding Mr. Warner's and Mr. Pantani's future
management of Warner's day-to-day operations and Harvard Bioscience's
acquisition of Warner being immediately accretive and any inference as to
Harvard Bioscience's ability to expand its range of products and any inference
as to Harvard Bioscience's ability to grow revenues 30% to 35% per year. Such
statements are subject to uncertainties and risks that could cause the actual
results, performance or achievements of Harvard Bioscience to differ materially
from anticipated future results, performance or achievements expressed or
implied by such forward-looking statements. These uncertainties and risks
include the risk that Mr. Warner and Mr. Pantani will elect to terminate their
employment with Harvard Bioscience or will otherwise cease to remain with the
Harvard Bioscience, the risk that Harvard Bioscience will be 



<PAGE>

unable to develop or acquire additional products to expand its product
offerings, the risk that Harvard Bioscience will experience unforeseen problems
affecting its ability to achieve revenue growth consistent with its goals or
projections, uncertainties regarding the financial impact of the Warner
acquisition on Harvard Bioscience's results of operations in future periods and
particularly regarding whether its impact will be accretive to Harvard
Bioscience's earnings, uncertainties regarding the impact of the events
disclosed in this release on Harvard Bioscience's operations and its stock
price, and other risks detailed in Harvard Bioscience's Securities and Exchange
Commission filings.

Press releases and our product catalog can be found on our web site,
http://www.harvardbioscience.com.

SOURCE Harvard Bioscience, Inc.

CONTACT: Jim Warren, CFO, jwarren@harvardbioscience.com, David Green, President,
dgreen@harvardbioscience.com, or Chane Graziano, CEO,
cgraziano@harvardbioscience.com, all of Harvard Bioscience